UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022692
Receipt number R000026150
Scientific Title Study to investigate the interchangeability between different polio vaccines (OPV, IPV and DPT-IPV) based on immunogenicity and safety
Date of disclosure of the study information 2016/06/10
Last modified on 2017/06/12 09:41:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study to investigate the interchangeability between different polio vaccines (OPV, IPV and DPT-IPV) based on immunogenicity and safety

Acronym

Study of interchangeability between polio vaccines

Scientific Title

Study to investigate the interchangeability between different polio vaccines (OPV, IPV and DPT-IPV) based on immunogenicity and safety

Scientific Title:Acronym

Study of interchangeability between polio vaccines

Region

Japan


Condition

Condition

Polio

Classification by specialty

Child

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the interchangeability among these three types of polio vaccines (OPV, IPV and DPT-IPV)

Basic objectives2

Others

Basic objectives -Others

Immunogenicity, Safety

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

To assess the immunogenicity of polio vaccines, geometric mean titer (GMT), fold rise, and seroprotection proportion were calculated.

Key secondary outcomes

To analyze descriptive information on safety (post-vaccination adverse reactions), frequencies of each local and systemic reaction were calculated.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

4

Purpose of intervention

Prevention

Type of intervention

Vaccine

Interventions/Control_1

For infants who had received one dose of oral polio vaccine, Doses 2-4 were administered using DPT-IPV.

Interventions/Control_2

For infants who had received one dose of oral polio vaccine and DPT vaccines, Doses 2-4 were administered using IPV.

Interventions/Control_3

For polio vaccine-naive infants, Doses 1-2 were administered using DPT-IPV, and Doses 3-4 were administered using IPV.

Interventions/Control_4

For polio vaccine-naive infants, Doses 1-2 were administered using IPV, and Doses 3-4 were administered using DPT-IPV.

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

3 months-old <=

Age-upper limit

74 months-old >=

Gender

Male and Female

Key inclusion criteria

Healthy infants and children aged 3-74 months without any history of acute poliomyelitis, diphtheria, pertussis, or tetanus.

Key exclusion criteria

Obvious history of anaphylaxis caused by food or drugs; receipt of any live vaccine within the preceding 27 days; receipt of any inactivated vaccine within the preceding 6 days; receipt of any blood transfusion or gamma globulin preparation within the preceding 3 months; receipt of immunosuppressants (except for external use), gamma globulin preparation (200 mg/kg or more), prednisolone (2 mg/kg/day or more) as an adrenocorticosteroid preparation (except for external use), or immunosuppressive therapy (including radiotherapy) within the preceding 6 months; congenital or acquired immunodeficiency; participation in a separate clinical trial (including individuals who had completed a clinical trial in the last 6 months); and individuals who pediatricians deemed ineligible to participate in this study.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshio Hirota

Organization

College of Healthcare Management

Division name

President

Zip code


Address

960-4, Takayanagi, Setaka-machi, Miyama-shi, Fukuoka, 835-0018

TEL

0944-67-7007

Email

yos-hirota@healthcare-m.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Motoki Ishibashi

Organization

PS Clinic, Medical Co. LTA

Division name

Clinical Research Department

Zip code


Address

6-18, Ten-ya-machi, Hakata-ku, Fukuoka-city, Fukuoka 812-0025

TEL

092-283-7777

Homepage URL


Email

motoki-ishibashi@lta-med.com


Sponsor or person

Institute

College of Healthcare Management

Institute

Department

Personal name



Funding Source

Organization

a research grant for Research on Emerging and Re-emerging Infectious Diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labor and Welfare, Japan

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Sanofi Pasteur S.A.
The Research Foundation for Microbial Diseases of Osaka University

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人しんどう小児科医院(福岡県)、高崎小児科医院(福岡県)、医療法人横山小児科医院(福岡県)、医療法人やました小児科医院(福岡県)、医療法人しばおクリニック(福岡県)、大阪市立大学大学院医学研究科公衆衛生学(大阪府)、医療法人相生会ピーエスクリニック(福岡県)


Other administrative information

Date of disclosure of the study information

2016 Year 06 Month 10 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications

http://insights.ovid.com/pubmed?pmid=28591046

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2011 Year 10 Month 31 Day

Date of IRB


Anticipated trial start date

2011 Year 11 Month 15 Day

Last follow-up date

2018 Year 12 Month 31 Day

Date of closure to data entry

2019 Year 03 Month 31 Day

Date trial data considered complete

2019 Year 03 Month 31 Day

Date analysis concluded

2020 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 06 Month 10 Day

Last modified on

2017 Year 06 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026150


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name